How I manage frontline transplant-ineligible multiple myeloma

  • Daniele Derudas | daniele.derudas@aob.it S.C. di Ematologia e C.T.M.O. – Ospedale Oncologico di Riferimento Regionale “A. Businco”, Cagliari (CA), Italy.
  • Francesca Capraro S.C. di Ematologia e C.T.M.O. – Ospedale Oncologico di Riferimento Regionale “A. Businco”, Cagliari (CA), Italy.
  • Giovanni Martinelli Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.
  • Claudio Cerchione Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.

Abstract

The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or complications of disease. The management of transplant ineligible MM patients is based on the balance safety and efficacy of the new available regimen and a careful assessment of the frailty status is mandatory to define the goals. In this review we discuss of the clinical dilemmas in the management and define how to manage them based on the evidence from clinical trials and “real life” experience.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

(1) Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23 (1): 3-9, DOI: https://doi.org/10.1038/leu.2008.291

(2) Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e48. DOI: https://doi.org/10.1016/S1470-2045(14)70442-5

(3) Howlander N, Noone AM, Krapcho M, Miller D, Bishop K, Alterkruse SF et al. SEER Cancer Statistics Review. 1975 – 2013. National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web sire, April 2016. SEER Website 2015. http://seer.cancer.gov/archive/csr/1975_2013/.

(4) Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladè J, Mateos MV et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118 (17):4519-29. DOI: https://doi.org/10.1182/blood-2011-06-358812

(5) van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother 2013;14:1569–73. DOI: https://doi.org/10.1517/14656566.2013.805746

(6) 31 Zeegman

(7) Mateos MV, San Miguel JF: How should we treat newly diagnosed multiple myeloma patients?. Hematology Am Soc Hematol Educ Program. 2013, 2013:488-95. DOI: https://doi.org/10.1182/asheducation-2013.1.488

(8) Pulte D, Gondos A, Brenner H: Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011, 16:1600-1603. DOI: https://doi.org/10.1634/theoncologist.2011-0229

(9) Kumar SK, Rajkumar SV, Dispenzieri A, et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, 111:2516-20. DOI: https://doi.org/10.1182/blood-2007-10-116129

(10) Morgan GJ. Transplants for the elderly in myeloma. Blood. 2013;122:1332-1334. DOI: https://doi.org/10.1182/blood-2013-07-510941

(11) Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076-3084. DOI: https://doi.org/10.1182/blood-2014-09-568915

(12) Moreau P, San Miguel J, Sonneveld P, et al; ESMO Guidelines Committee. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52-iv61. DOI: https://doi.org/10.1093/annonc/mdx096

(13) Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017: NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15:230-269. DOI: https://doi.org/10.6004/jnccn.2017.0023

(14) Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017; 1:282-287. DOI: https://doi.org/10.1182/bloodadvances.2016002493

(15) Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209-215. DOI: https://doi.org/10.1038/bmt.2014.255

(16) Nadiminti K, Strouse C, Vikas P, et al.A single autologous stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) patients: safety and response results from the prospective phase II Trial (NCT01849783). Presented at: 60th Annual Meeting of the American Society of Hematology. San Diego, CA; 2018. Abstract 2153. DOI: https://doi.org/10.1182/blood-2018-99-118443

(17) Merz M, Neben K, Raab MS, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25:189-195. DOI: https://doi.org/10.1093/annonc/mdt509

(18) Ozaki S, Harada T, Saitoh T, et al; Japanese Society of Myeloma; European Myeloma Network. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation: a multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132:211-219. DOI: https://doi.org/10.1159/000357394

(19) Sanchez L, Sylvester M, Parrondo R, et al. In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study. Biol Blood Marrow Transplant. 2017;23:1203-1207. DOI: https://doi.org/10.1016/j.bbmt.2017.03.012

(20) Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122:1376-1383. DOI: https://doi.org/10.1182/blood-2013-02-483073

(21) Dimopoulos MA, Mateos M-V, Cavo M, et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): ALCYONE. Presented at: 60th Annual Meeting of the American Society of Hematology. San Diego, CA; 2018. Abstract 156.

(22) Facon T, Kumar SK, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Presented at: 60th Annual Meeting of the American Society of Hematology. San Diego, CA; 2018. Abstract LBA-2. DOI: https://doi.org/10.1182/blood-2018-120737

(23) Dimopoulos MA, Mateos M-V, Cavo M, et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): ALCYONE. Presented at: 60th Annual Meeting of the American Society of Hematology. San Diego, CA; 2018. Abstract 156. ? DOI: https://doi.org/10.1182/blood-2018-156

(24) Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014; 111(3):628-636. DOI: https://doi.org/10.1038/bjc.2014.307

(25) Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98:980–7. DOI: https://doi.org/10.3324/haematol.2012.075051

(26) Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patient: an International Myeloma Working Group report. Blood 125 (13) (2015) 2068-2074

(27) Gavriatopoulou M, Fotiou D, Roussou M,at al. Vulnerability variables among octagenarians myeloma patients: a single-center analysis in 110 patients. ASH 2017, Blood (2017) 3152

(28) Engelhardt M, Domm AS, Dold SM, Ihorst G et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102 (5) (2017) 910-921 DOI: https://doi.org/10.3324/haematol.2016.162693

(29) Murillo A, Cronin AM, Laubach JP, Hshiesh TT et al. Performance of the International Myeloma Working Group myeloma frailty score among 75 and older. J Geriatr.Oncol. 10(3) (2019) 486-489. DOI: https://doi.org/10.1016/j.jgo.2018.10.010

(30) Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D et al. Complete response correlates with long-term progression-free survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025-31. DOI: https://doi.org/10.1182/blood-2010-09-307645

(31) Facon T, Mary JY, Hulin C, Benboubker L Attal M et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet. 2007; 370(9594):1209-18. DOI: https://doi.org/10.1016/S0140-6736(07)61537-2

(32) Waage A, Gimsing P, Fayers P, Abildgaard N et al. Melphalan and prednisone plus thalidomide or plascebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-12. DOI: https://doi.org/10.1182/blood-2009-08-237974

(33) Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol. 2010;28(19):3160-6 DOI: https://doi.org/10.1200/JCO.2009.26.1610

(34) Hulin C, Gacon T, Rodon P, Pegourie B et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-70. DOI: https://doi.org/10.1200/JCO.2008.21.0948

(35) Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86(1):16-22. DOI: https://doi.org/10.1111/j.1600-0609.2010.01524.x

(36) Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso a et al. A randomized trial with melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma. 2011;52(10):1942-8 DOI: https://doi.org/10.3109/10428194.2011.584006

(37) San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus Melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17. DOI: https://doi.org/10.1056/NEJMoa0801479

(38) Mateos M-V, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and im- pact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259–66 DOI: https://doi.org/10.1200/JCO.2009.26.0638

(39) Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745–53. DOI: https://doi.org/10.1182/blood-2010-07-294983

(40) Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431–40. DOI: https://doi.org/10.1016/S1470-2045(11)70081-X

(41) Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib- melphalan-prednisone-thalidomide followed by maintenance with bortezomib- thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101–9. DOI: https://doi.org/10.1200/JCO.2010.29.8216

(42) Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for in- itial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014;32:634–40 DOI: https://doi.org/10.1200/JCO.2013.52.0023

(43) Mateos M-V, Oriol A, Martínez-López J, Gutiérrez N, Teruel A-I, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and pre- dnisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with un- treated multiple myelom. Lancet Oncol 2010;11:934–41 DOI: https://doi.org/10.1016/S1470-2045(10)70187-X

(44) Mateos M-V, Oriol A, Martinez-Lopez J, Teruel A-I, Lopez de la Guia A, Lopez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014;124:1887–93 DOI: https://doi.org/10.1182/blood-2014-05-573733

(45) Stewart AK, Jacobus S, Fonseca R, Weiss M et al. Melphalan, prednisone and thalidomide versus melphalan, prednisone and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015;126(11):1294-301. DOI: https://doi.org/10.1182/blood-2014-12-613927

(46) Palumbo A, Hajek R, Delforge M, Kropff M et al. Continuous lenalidomidetratment for newly diagnosed multiple myeloma. N Engl J med. 2012;366(19):1759-69. Landmark phase III study establishing continuous lenalidomide-based therapy as a standard of care for transplant ineligible MM.

(47) Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906–17. DOI: https://doi.org/10.1056/NEJMoa1402551

(48) Delforge M, Minuk L, Eisenmann J-C, Arnulf B, Canepa L, Fragasso A, et al. Health- related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica 2015;100:826–33. DOI: https://doi.org/10.3324/haematol.2014.120121

(49) Durie BGM, Hoering A, Abidi MH, Rajkumar Sv, Epstein J et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open-label, phase 3 trial. Lancet. 2016. Large phase III trial establishing bortezomib-lenalidomide-dexamethasone (VRd) therapy as the current standard of care for transplant ineligible MM in the US. DOI: https://doi.org/10.1016/S0140-6736(16)31594-X

(50) O’Donnell E, Laubach JP, Yee AJ, Huff CA et al. A phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD lite) for transplant-ineligicle patents with newly diagnosed multiple myeloma. Blood. 2014;124(21):3454. DOI: https://doi.org/10.1182/blood.V124.21.3454.3454

(51) Mateos M-V, Dimopoulos Ma Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J med. 2018;378(6):518-528. DOI: https://doi.org/10.1056/NEJMoa1714678

(52) Facon T, Kumar S, Plesner T, et al. daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115. DOI: https://doi.org/10.1056/NEJMoa1817249

(53) Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95 (5):548-567. DOI: https://doi.org/10.1002/ajh.25791

(54) Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E,et al: NCCN Guidelines Insights: Multiple Myeloma, version1.2020. J Natl Compr Can Netw 2019 Oct 1;17 (10):1154-1165. DOI: https://doi.org/10.6004/jnccn.2019.0049

(55) Larocca A, Palumbo a. I how treat fragile myeloma patients. Blood. 2015;126(19):2179-85. DOI: https://doi.org/10.1182/blood-2015-05-612960

(56) Kumar SK, Berdeja JG, Niesvizky R, Lional S et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2study. Lancet Oncol. 2014;15(13). DOI: https://doi.org/10.1016/S1470-2045(14)71125-8

(57) Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Eng J Med. 2016;374(17):1621-34. DOI: https://doi.org/10.1056/NEJMoa1516282

(58) Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Exert Rev Hematol. 2018;11(10):761-71. DOI: https://doi.org/10.1080/17474086.2018.1518129

(59) Lional S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Eng J med. 2015;373(7):621-31. DOI: https://doi.org/10.1056/NEJMoa1505654

(60) Domopoulos Ma, Dytfeld D, Grosicki S, Moreau P, et al. Elotuzumab plus pomalidomide and dexamethasone for multliple myeloma. N Engl J Med. 2018;379(19):1811-22. DOI: https://doi.org/10.1056/NEJMoa1805762

(61) Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. Lancet Oncol. 2016; 17(1).

(62) Dimopoulos MA, Stewart AK, Masszi T, Spicka L, Oriol A, et al. Carfilzomib, lenalidomide e dexamethasone in patients with relapsed multiple myeloma categorized by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017; 177(3). 404-413. DOI: https://doi.org/10.1111/bjh.14549

(63) Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, et al. Daratumumab, Lenalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2016, 375(14), 1319-1331. DOI: https://doi.org/10.1056/NEJMoa1607751

(64) Palumbo A, Chanan-Khan K, Weisel K, et al. Daratumumab, Bortezomib and Dexamethasone for Multiple Myeloma. N Engl J Med 2016, 375(8) 754-766. DOI: https://doi.org/10.1056/NEJMoa1606038

Published
2020-09-21
Keywords:
Multiple Myeloma, transplant-ineligible
Statistics
  • Abstract views: 448

  • PDF: 392
  • HTML: 0
How to Cite
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2020). How I manage frontline transplant-ineligible multiple myeloma. Hematology Reports, 12(s1). https://doi.org/10.4081/hr.2020.8956